On September 21, 2015 Endocyte, Inc. (NASDAQ:ECYT), a leader in developing targeted small molecule drug conjugates (SMDCs) and companion imaging agents for personalized therapy, reported that data from ongoing phase 1 trials of Endocyte’s SMDC EC1456 will be presented at the European Cancer Congress 2015, being held Sept. 25 – 29, 2015, in Vienna, Austria (Press release, Endocyte, SEP 21, 2015, View Source [SID:1234507511]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation materials will be available on Endocyte’s website following presentation at the conference.

Presentation is as follows:

Poster Presentation: An ongoing Phase 1 dose-escalation study of the folic acid-tubulysin in small-molecule drug conjugate (SMDC) folate-tubulysin EC1456
When: Sunday, Sept. 27, 16:45 – 18:45 p.m. CEST
Poster Session: Early Drug Development
Presenter: Martin J. Edelman, University of Maryland Greenebaum Cancer Center, Baltimore

About EC1456

EC1456 is an investigational proprietary, injectable, SMDC consisting of folate (vitamin B9) linked to a potent cytotoxic agent, tubulysin B hydrazide (TubBH). EC1456 is wholly owned by Endocyte. TubBH is a member of the tubulysin class of anti-neoplastic agents that inhibit the polymerization of tubulin into microtubules, a critical component during cell division. The targeting ligand folate, essential for cell division, has been investigated with vintafolide. EC1456 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors (ClinicalTrials.gov Identifier: NCT01999738).